Merck’s oral cholesterol-lowering drug shows similar efficacy to injectable predecessors as it moves to PhIII: #ACC23

NEW ORLEANS — In back-to-back presentations on Monday with its Phase III data on a drug for pulmonary arterial hypertension, Merck unveiled new mid-stage data on an oral cholesterol-lowering drug for heart disease.

The 381-person Phase II study tested four doses of Merck’s oral PCSK9 inhibitor...

Click to view original post